Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tuberculosis vaccines: current status and future prospects.

Helen Fletcher1, Helen McShane

  • 1University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ, UK. Helen.Fletcher@ndm.ox.ac.uk

Expert Opinion on Emerging Drugs
|April 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge model.

Cell reports. Medicine·2026
Same author

Domain arrangement-driven immunogenicity of a computationally designed mRNA vaccine targeting PPE68, IrtA, and PE9 of Mycobacterium tuberculosis.

Scientific reports·2026
Same author

Enhancing tuberculosis vaccine efficacy with a heterologous mRNA-ChAdOx1 prime-pull strategy targeting lung-resident memory T cells.

Frontiers in immunology·2026
Same author

The influence of murine cytomegalovirus infection on susceptibility to mycobacterial infection.

iScience·2026
Same author

Menaquinone depletion resensitises bedaquiline-resistant tuberculosis.

bioRxiv : the preprint server for biology·2026
Same author

Quantitative measures of human <i>Cytomegalovirus</i> infection and their associations with tuberculosis disease progression and <i>Mycobacterium tuberculosis</i> infection.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2025

New tuberculosis vaccines are urgently needed as current treatments fail. Boosting existing Bacille Calmette-Guérin (BCG) vaccination is a viable strategy, but requires identifying protection correlates and reducing trial costs.

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Current tuberculosis (TB) chemotherapy and Bacille Calmette-Guérin (BCG) vaccination have not controlled the global TB epidemic.
  • BCG offers partial protection in children, suggesting a prime-boost strategy with a new vaccine is a promising approach.

Purpose of the Study:

  • To highlight the urgent need for novel tuberculosis vaccines.
  • To discuss the ethical and logistical feasibility of using a prime-boost strategy with BCG.
  • To emphasize the importance of identifying correlates of protection and reducing clinical trial costs.

Main Methods:

  • This study is a review and discussion of the current landscape of tuberculosis vaccine development.
  • It analyzes the economic and ethical considerations for advancing new TB vaccines.

Related Experiment Videos

  • It stresses the need for biomarkers to guide vaccine efficacy testing.

    • Main Results:

    • The development of effective tuberculosis vaccines is a global health priority.
    • Identifying correlates of protection is crucial for selecting promising vaccine candidates for efficacy trials.
    • Reducing the financial risks and costs associated with clinical trials is essential.

    Conclusions:

    • A second vaccine to boost BCG is the most ethical and feasible strategy for improving tuberculosis control.
    • Incentives like orphan drug status are needed to encourage industrial investment in vaccine development.
    • Further research into correlates of protection and cost-effective clinical trials will accelerate the development of urgently needed tuberculosis vaccines.